Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma

Figure 1

Abdominal MRI scans for Patient 1 (a–c), Patient 2 (d–f), and Patient 3 (g–i). MRI scans for Patient 1: (a) at diagnosis, (b) following induction therapy with eight cycles of COJEC, a cycle of adjuvant dinutuximab beta, and two cycles of adjuvant TVD, and (c) at the end of maintenance therapy with dinutuximab beta. MRI scans for Patient 2: (d) at diagnosis, (e) following induction therapy with eight cycles of COJEC, and (f) following three cycles of dinutuximab beta maintenance therapy. MRI scans for Patient 3: (g) at diagnosis, (h) following induction therapy with seven cycles of COJEC, and (i) following three cycles of second-line immunochemotherapy with irinotecan/temozolomide and dinutuximab beta and surgery of the primary abdominal tumor.